CN104529939B - 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 - Google Patents

3,7-二氨基-10h-吩噻嗪化合物盐及其用途 Download PDF

Info

Publication number
CN104529939B
CN104529939B CN201510002371.8A CN201510002371A CN104529939B CN 104529939 B CN104529939 B CN 104529939B CN 201510002371 A CN201510002371 A CN 201510002371A CN 104529939 B CN104529939 B CN 104529939B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
albumen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510002371.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104529939A (zh
Inventor
克劳德.M.维希克
珍妮特.E.里卡德
查尔斯.R.哈林顿
戴维.霍斯利
约翰.M.D.斯托雷
科林.马歇尔
詹姆斯.P.辛克莱
托马斯.C.巴德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104529939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN104529939A publication Critical patent/CN104529939A/zh
Application granted granted Critical
Publication of CN104529939B publication Critical patent/CN104529939B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
CN201510002371.8A 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 Active CN104529939B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29
US60/786,690 2006-03-29
CN200780020349.XA CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780020349.XA Division CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途

Publications (2)

Publication Number Publication Date
CN104529939A CN104529939A (zh) 2015-04-22
CN104529939B true CN104529939B (zh) 2019-05-07

Family

ID=38421429

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201510002365.2A Active CN104606199B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN200780020349.XA Active CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途
CN201811196758.1A Active CN109384741B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN201410269784.8A Active CN104119294B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN201510002371.8A Active CN104529939B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN201510002365.2A Active CN104606199B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN200780020349.XA Active CN101460472B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪盐及其用途
CN201811196758.1A Active CN109384741B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
CN201410269784.8A Active CN104119294B (zh) 2006-03-29 2007-03-28 3,7-二氨基-10h-吩噻嗪化合物的制备方法

Country Status (18)

Country Link
US (5) US7888350B2 (enExample)
EP (1) EP2013191B3 (enExample)
JP (3) JP5520043B2 (enExample)
KR (1) KR100983301B1 (enExample)
CN (5) CN104606199B (enExample)
AT (1) ATE478058T3 (enExample)
AU (1) AU2007231124B2 (enExample)
CA (1) CA2646163C (enExample)
DE (1) DE602007008550D1 (enExample)
DK (1) DK2013191T6 (enExample)
EA (1) EA014552B1 (enExample)
ES (1) ES2349322T7 (enExample)
HR (1) HRP20100614T4 (enExample)
IL (2) IL194516A (enExample)
MY (1) MY143757A (enExample)
PL (1) PL2013191T6 (enExample)
PT (1) PT2013191E (enExample)
WO (1) WO2007110627A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790881B2 (en) 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
CA2645946C (en) 2006-03-29 2014-04-01 Wista Laboratories Ltd. Inhibitors of protein aggregation
DK2013191T6 (en) * 2006-03-29 2019-04-23 Wista Lab Ltd 3,7-Diamino-10H-phenothiazine salts and their use
PT3121169T (pt) 2006-07-11 2022-05-13 Wista Lab Ltd Processos de síntese e/ou purificação de compostos diaminofenotiazínio
JP2010523591A (ja) * 2007-04-03 2010-07-15 プロセッタ バイオコンフォーマティクス インコーポレイテッド 抗ウイルス処置
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Wista Laboratories Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
FR2920775B1 (fr) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
PL2205245T3 (pl) * 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
MX367131B (es) * 2008-12-10 2019-08-06 Wista Lab Ltd Sales de xantilio 3,6-disustituidas.
ES2659091T3 (es) * 2009-09-24 2018-03-13 Wista Laboratories Ltd. Pentahidrato de cloruro de metiltioninio, preparación y uso farmacéutico del mismo
MX2012003083A (es) * 2009-09-24 2012-04-30 Wista Lab Ltd Clorhidratos de metiltioninio (azul de metileno) cristalinos.
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
CN102958525B (zh) 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
CA2818068C (en) 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
KR20230058533A (ko) 2016-07-25 2023-05-03 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) * 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
EP4364801B1 (en) 2018-07-26 2025-11-12 TauRx Therapeutics Management Ltd. Optimised dosage of diaminophenothiazines in populations
SG11202102139YA (en) 2018-09-05 2021-04-29 Genting Taurx Diagnostic Centre Sdn Bhd Network methods for neurodegenerative diseases
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
JP2023524146A (ja) * 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド 低酸素血症の治療に使用されるメチルチオニニウム化合物
EP4146223A1 (en) 2020-05-05 2023-03-15 WisTa Laboratories Ltd. Methylthioninium compounds for use in the treatment of covid-19
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) * 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
JP2025518248A (ja) 2022-05-31 2025-06-12 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム（ｍｔ）含有化合物を利用した神経変性障害の処置
CN119947729A (zh) 2022-09-21 2025-05-06 罗颍诗 二氨基吩噻嗪的口服制剂及其在治疗和/或预防疾病中的制备和使用方法
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease
CN117447421A (zh) * 2023-10-30 2024-01-26 上海沃凯生物技术有限公司 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
CN1179829A (zh) * 1995-03-27 1998-04-22 霍夫曼-拉罗奇有限公司 Tau－Tau结合的抑制
CN1496404A (zh) * 2001-01-15 2004-05-12 ����˹���ѧ���»� 与神经变性疾病中蛋白聚集相关的物质和方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (enExample) * 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4622395A (en) * 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
US4647525A (en) * 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
WO1993003177A1 (en) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ATE386115T1 (de) 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
WO1996004915A1 (en) 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
EP0973383A4 (en) 1997-01-21 2001-08-22 American Nat Red Cross INTRACELLULAR AND EXTRACELLULAR DECONTAMINATION OF TOTAL BLOOD AND BLOOD COMPONENTS USING AMPHIPHILIC DYES PHENOTIAZIN-5-IUM AND LIGHT
AU4322999A (en) 1998-06-01 1999-12-20 Advanced Research And Technology Institute, Inc. Methods and compositions for diagnosing tauopathies
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
BRPI0416928A (pt) 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
US7790881B2 (en) * 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
ES2736160T3 (es) 2004-09-23 2019-12-26 Wista Lab Ltd Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
PL2001556T3 (pl) 2006-03-29 2015-03-31 Wista Lab Ltd Związki tioniny i ich zastosowanie
DK2013191T6 (en) * 2006-03-29 2019-04-23 Wista Lab Ltd 3,7-Diamino-10H-phenothiazine salts and their use
CA2645946C (en) 2006-03-29 2014-04-01 Wista Laboratories Ltd. Inhibitors of protein aggregation
PT3121169T (pt) 2006-07-11 2022-05-13 Wista Lab Ltd Processos de síntese e/ou purificação de compostos diaminofenotiazínio
AU2008265045B2 (en) 2007-06-19 2014-02-27 Wista Laboratories Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PL2205245T3 (pl) 2007-10-03 2015-12-31 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7317787B2 (ja) 2020-10-19 2023-07-31 トヨタ自動車株式会社 排ガス浄化装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5220009A (en) * 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
CN1179829A (zh) * 1995-03-27 1998-04-22 霍夫曼-拉罗奇有限公司 Tau－Tau结合的抑制
CN1496404A (zh) * 2001-01-15 2004-05-12 ����˹���ѧ���»� 与神经变性疾病中蛋白聚集相关的物质和方法

Also Published As

Publication number Publication date
CN101460472B (zh) 2015-06-17
US7888350B2 (en) 2011-02-15
US11951110B2 (en) 2024-04-09
CA2646163A1 (en) 2007-10-04
ES2349322T3 (es) 2010-12-29
CN104606199A (zh) 2015-05-13
IL194516A (en) 2015-02-26
EA014552B1 (ru) 2010-12-30
DK2013191T6 (en) 2019-04-23
EP2013191A2 (en) 2009-01-14
CN109384741A (zh) 2019-02-26
WO2007110627A2 (en) 2007-10-04
IL231890A (en) 2016-10-31
HRP20100614T4 (hr) 2019-08-09
US20090054419A1 (en) 2009-02-26
HK1126480A1 (en) 2009-09-04
HK1210047A1 (en) 2016-04-15
CN109384741B (zh) 2023-01-06
AU2007231124A1 (en) 2007-10-04
PL2013191T6 (pl) 2019-07-31
ES2349322T7 (es) 2019-10-17
CN104606199B (zh) 2022-09-13
DE602007008550D1 (de) 2010-09-30
US12324810B2 (en) 2025-06-10
EA200870384A1 (ru) 2009-04-28
JP2013121985A (ja) 2013-06-20
EP2013191B1 (en) 2010-08-18
JP5520043B2 (ja) 2014-06-11
CN104119294B (zh) 2018-10-30
CA2646163F (en) 2007-10-04
PL2013191T3 (pl) 2011-02-28
JP2014055165A (ja) 2014-03-27
US20250325557A1 (en) 2025-10-23
PT2013191E (pt) 2010-10-29
US20160051559A1 (en) 2016-02-25
KR20080110879A (ko) 2008-12-19
CN104529939A (zh) 2015-04-22
CA2646163C (en) 2011-03-15
CN104119294A (zh) 2014-10-29
IL194516A0 (en) 2009-08-03
AU2007231124B2 (en) 2013-02-21
CN101460472A (zh) 2009-06-17
MY143757A (en) 2011-07-15
WO2007110627A3 (en) 2007-11-22
JP5814957B2 (ja) 2015-11-17
DK2013191T3 (da) 2010-11-22
HRP20100614T1 (hr) 2010-12-31
US20220152038A1 (en) 2022-05-19
EP2013191B3 (en) 2019-02-27
HK1209417A1 (en) 2016-04-01
ATE478058T3 (de) 2010-09-15
JP2009531403A (ja) 2009-09-03
IL231890A0 (en) 2014-05-28
HK1199444A1 (en) 2015-07-03
KR100983301B1 (ko) 2010-09-20
US11344558B2 (en) 2022-05-31
US20240245700A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
CN104529939B (zh) 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
US9174954B2 (en) 3,7-diamino-10H-phenothiazine salts and their use
HK1261726A1 (en) 3,7-diamino-10h-phenothiazine salts and their use
HK1261726B (en) 3,7-diamino-10h-phenothiazine salts and their use
AU2013200732B2 (en) 3,7-diamino-10H-phenothiazine salts and their use
HK1209417B (zh) 3，7-二氨基-10h-吩噻嗪化合物盐及其用途
HK1199444B (zh) 3，7-二氨基-10h-吩噻嗪化合物的制备方法
HK1210047B (en) 3,7-diamino-10h-phenothiazine salts and their use

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1209417

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant